News & Blog

FARA Celebrates 16 Years of Funding Adaptive Cycling Equipment Through The Ataxian Athlete Initiative (AAI) 

United Against Ataxia Hill Day 2024 – Registration open!

August 2024 – Advocacy Newsletter

Join us for FA Community Conversations – Genetic Medicine on August 29, 2024

Larimar Therapeutics Reports Several Updates on Nomlabofusp FA Program in Q2 2024 Operating and Financial Results

Job Opening – Accounting Specialist

FARA Advocates for Effective Inclusion of Children Early in Clinical Trials at Pediatric Inclusion Roundtable

2023 Donor Impact Report

LEXEO Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

June 2024 – Advocacy Newsletter

C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with new Friedreich’s Ataxia Data

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia